Get the Stockscreener App
0.7643
0.57%
0.0043
Nautilus Biotechnology Inc stock is traded at $0.7643, with a volume of 139.94K.
It is up +0.57% in the last 24 hours and up +4.70% over the past month.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
See More
Previous Close:
$0.76
Open:
$0.77
24h Volume:
139.94K
Relative Volume:
0.48
Market Cap:
$96.42M
Revenue:
-
Net Income/Loss:
$-70.78M
P/E Ratio:
-1.3648
EPS:
-0.56
Net Cash Flow:
$-61.27M
1W Performance:
+0.84%
1M Performance:
+4.70%
6M Performance:
-55.30%
1Y Performance:
-69.55%
1-Day Range:
$0.7384
$0.7872
1-Week Range:
$0.7301
$0.83
52-Week Range:
$0.66
$3.09
Nautilus Biotechnology Inc Stock (NAUT) Company Profile
Name
Nautilus Biotechnology Inc
Sector
Industry
Phone
206-333-2001
Address
2701 EASTLAKE AVE EAST, SEATTLE
Compare NAUT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAUT
Nautilus Biotechnology Inc
|
0.7643 | 95.87M | 0 | -70.78M | -61.27M | -0.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Nautilus Biotechnology Inc Stock (NAUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Neutral → Sell |
| Jun-27-24 | Initiated | Guggenheim | Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-02-21 | Initiated | Cowen | Outperform |
| Aug-04-21 | Initiated | Goldman | Neutral |
| Jul-13-21 | Initiated | Jefferies | Buy |
View All
Nautilus Biotechnology Inc Stock (NAUT) Latest News
What makes Nautilus Biotechnology Inc. stock price move sharplyTactical Trade Setup With Entry Optimizer - Newser
Nautilus Biotechnology’s Earnings Call: Progress Amid Challenges - TipRanks
Is Nautilus Biotechnology Inc. Stock a Smart Buy in 2025 Investment Analysis InsideBreakout Screener With Alert Based Timing - Newser
What to expect from Nautilus Biotechnology Inc. in the next 30 daysEntry Confirmation Using Short-Term Forecasting - Newser
Technical signs of recovery in Nautilus Biotechnology Inc.Weekly Stock Picks with Trend Confidence - Newser
Nautilus Biotechnology’s Q2 2025 Financial Highlights - TipRanks
Using Python tools to backtest Nautilus Biotechnology Inc. strategiesBuy Point Strategy with Profit Protection - Newser
Nautilus Biotechnology's Q2 2025: Unpacking Contradictions in Proteoform Launch, Revenue, and Partnerships - AInvest
What is the dividend policy of Nautilus Biotechnology Inc. stockMarket Forecast Outlook With Proven Results - jammulinksnews.com
Will Nautilus Biotechnology Inc. stock go up soonEntry Opportunity Screener with Confirmation - Newser
Nautilus Biotechnology Reports Second Quarter 2025 Financial Results - GlobeNewswire
Nautilus Biotechnology, Inc. SEC 10-Q Report - TradingView
What catalysts could drive Nautilus Biotechnology Inc. stock higher in 2025Real Time Alerts For Fast Growth - jammulinksnews.com
What is Nautilus Biotechnology Inc. company’s growth strategyTop Growth Review With High Returns - jammulinksnews.com
Earnings call transcript: Nautilus Biotechnology beats EPS forecast in Q2 2025 - Investing.com Canada
Earnings call transcript: Nautilus Biotechnology beats EPS forecast in Q2 2025 By Investing.com - Investing.com South Africa
Nautilus Biotechnology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Does Nautilus Biotechnology Inc. stock perform well during market downturnsBest Dividend Guidance For Fast Growth - jammulinksnews.com
What are analysts’ price targets for Nautilus Biotechnology Inc. in the next 12 monthsDaily Trading Opportunities For Consistent Profits - jammulinksnews.com
Signal strength of Nautilus Biotechnology Inc. stock in tech scannersFree Investment Plan With Growth Optimization - Newser
Key External Factors That Drive Nautilus Biotechnology Inc. Stock Price MovementsIntraday Signal Forecast for Fast Traders - Newser
How to interpret RSI for Nautilus Biotechnology Inc. stockDaily Investment Ideas with Market Insight - Newser
How Nautilus Biotechnology Inc. stock performs during market volatilityFree Fast Gaining Stock Screener Report - Newser
Nautilus Biotechnology Announces Agreement with the Allen - GlobeNewswire
Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics - The Manila Times
Nautilus Partners with Allen Institute to Advance Alzheimer's Tau Protein Research | NAUT Stock News - Stock Titan
Building trade automation scripts for Nautilus Biotechnology Inc.7-Day Equity Return Range Forecast Model - Newser
Momentum divergence signals in Nautilus Biotechnology Inc. chartROI Focused Setup Screener With Exit Markers - Newser
Why Nautilus Biotechnology Inc. stock attracts strong analyst attentionAI Trading Suggestions With Accuracy Focus Released - beatles.ru
Published on: 2025-07-29 18:27:27 - metal.it
Nautilus NAUT 2025Q2 Earnings Preview Downside Ahead on Projected EPS Decline - AInvest
How does Nautilus Biotechnology Inc. generate profit in a changing economyBoost your returns with professional guidance - jammulinksnews.com
Is it the right time to buy Nautilus Biotechnology Inc. stockMaximize gains with expert analysis - jammulinksnews.com
Technical Heatmap Flags Nautilus Biotechnology Inc. for WatchEntry and Exit Strategy Optimizer Tool Tested - metal.it
Real time breakdown of Nautilus Biotechnology Inc. stock performanceWeekly Outlook for Short Term Investors - Newser
How volatile is Nautilus Biotechnology Inc. stock compared to the marketCapitalize on momentum-driven opportunities - jammulinksnews.com
Should I hold or sell Nautilus Biotechnology Inc. stock in 2025Capitalize on emerging market opportunities - jammulinksnews.com
Is Nautilus Biotechnology Inc. a growth stock or a value stockSmart Portfolio Ideas For Fast Growth - jammulinksnews.com
What is the risk reward ratio of investing in Nautilus Biotechnology Inc. stockCapitalize on fast-moving market trends - jammulinksnews.com
Nautilus Biotechnology Inc Stock (NAUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):